Big Moving Stock keep track of the biggest moving stocks in the market.


Nasdaq: GOOG BIIB NFLX IBB AMZN TSLA ALXN ILMN AMGN CHTR WYNN COST GMCR SLXP VRTX CELG SBAC AAPL WDC
Nyse: V ACT LNKD AGN MCK IVV LMT GS SPG FDX MMM IBM HUM NOC PXD TWC APD CMI BDX GD
New Highs: SHW PPG ORLY WHR SPG BWLD AVB MMM HUM BXP LLL PANW HAIN VNO WDC CNC GPC CLX UNH HON

The Hot Industries

Health Care Plans 3
Diversified Machinery 2
Specialty Chemicals 2

The Hot Sectors

Services 4
Financial 4
Healthcare 3

ARIA Stock Chart


ARIA
Analyze

Sector:

Healthcare
Daily

Industry:

Biotechnology
Weekly

Employees:

307
Monthly

Website:

http://www.ariad.com

ARIA Ariad Pharmaceuticals Inc.

ARIAD Pharmaceuticals, Inc., an oncology company, focuses on the discovery, development, and commercialization of medicines for cancer patients. The company focuses on commercializing Iclusig (ponatinib), a cancer medicine; and developing additional molecularly targeted therapies to treat patients with blood cancers and solid tumors. Iclusig is a tyrosine kinase inhibitor (TKI) that is approved in the United States for the treatment of adult patients with chronic, accelerated, or blast phase chronic myeloid leukemia, who are resistant or intolerant to prior TKI therapy, as well as for the treatment of adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia, who are resistant or intolerant to prior TKI therapy. Its product pipeline consists of AP26113, an investigational dual inhibitor of anaplastic lymphoma kinase, which is being studied in a phase I/II clinical trial in patients with advanced solid tumors comprising non-small cell lung cancer; Ridaforolimus, an investigational mTOR inhibitor, which is being studied in multiple clinical trials in patients with various types of cancers; and AP1903, a small-molecule dimerizer drug. The company sells and markets Iclusig through specialty pharmacies and specialty distributors in the United States. It has collaboration and license agreement with Merck & Co., Inc. for the development, manufacture, and commercialization of ridaforolimus, for use in cancer; and license agreements with Medinol Ltd. and ICON Medical Corp. to develop and commercialize stents and other medical devices to deliver ridaforolimus. ARIAD Pharmaceuticals, Inc. was founded in 1991 and is headquartered in Cambridge, Massachusetts.

favicon

Aria Development Group and AQARAT Announce New Downtown Miami Mixed-Use Project

18 Dec 2014, 1:09 pmAria Development Group, together with AQARAT, announced its latest development in the heart of Downtown Miami's bourgeoning urban core. The mixed-use project, set to open in 2017, will feature luxury apartments ...
favicon

Biotech Stocks Technical Insight -- ARIAD Pharma, Geron, PDL BioPharma, Cytori Therapeutics, and Navidea Biopharma

18 Dec 2014, 7:28 amLONDON, December 18, 2014 /PRNewswire/ -- Investor-Edge has initiated coverage on the following equities: ARIAD Pharmaceuticals Inc. (NASDAQ: ARIA), Geron Corporation (NASDAQ: GERN), PDL BioPharma Inc. (NASDAQ: PDLI), Cytori Therapeutics Inc. (NASDAQ: CYTX), and Navidea...
favicon

Interesting ARIA Call Options For January 2015

11 Dec 2014, 11:15 amInteresting ARIA Call Options For January 2015
favicon

Will Ariad Pharmaceuticals (ARIA) Stock be Affected Today by This Analyst Action?

11 Dec 2014, 7:30 amNEW YORK (TheStreet) -- Shares of Ariad Pharmaceuticals are down 2.85% to $6.82 in pre-market trading after Credit Suisse downgraded the global oncology company to "underperform" from "neutral" and lowered its price target to $6 from $8. "Launches [are] still tepid in U.S. and EU. Metrics for the re-launch suggest Iclusig is reserved for the sicker patients and this trend is not likely to change ...
favicon

Analysts' Actions: AbbVie, Ariad, Lilly, Prologis, Toll Brothers

11 Dec 2014, 7:13 amNEW YORK (TheStreet) -- RATINGS CHANGES AbbVie was downgraded at Morgan Stanley to equal-weight from overweight. Twelve-month price target is $72. Stock is already pricing in potential for Hepatitis-C and Humira, Morgan Stanley said. Alico was upgraded to buy at TheStreet Ratings. You can view the full analysis from the report here: ALCO Ratings Report. Must Read: 12 Stocks Warren Buffett Loves ...
favicon

Health Care Sector Update for 12/11/2014: ARIA, STJ, KITE, MYL

11 Dec 2014, 7:07 amHealth Care Sector Update for 12/11/2014: ARIA, STJ, KITE, MYL
favicon

Why Ariad Pharmaceuticals, Inc. Stock Catapulted 19% Higher in November

5 Dec 2014, 8:30 amWhy Ariad Pharmaceuticals, Inc. Stock Catapulted 19% Higher in November
favicon

The Zacks Analyst Blog Highlights: Biogen Idec, Eli Lilly, AstraZeneca and Amgen

4 Dec 2014, 4:28 amThe Zacks Analyst Blog Highlights: Biogen Idec, Eli Lilly, AstraZeneca and Amgen
favicon

Ariad Pharmaceuticals (ARIA) Jumps: Stock Gains 9.7% - Tale of the Tape

25 Nov 2014, 9:31 amAriad Pharmaceuticals (ARIA) Jumps: Stock Gains 9.7% - Tale of the Tape
favicon

Ariad Pharmaceuticals (ARIA) Jumps: Stock Gains 9.7%

25 Nov 2014, 5:52 amAriad Pharmaceuticals (ARIA) was a big mover last session, as the company saw its shares rise nearly 10% on the day.